Studies have shown that tumor necrosis factor-alpha (TNF-α) and C-reactive protein levels at 24–28 weeks of gestation are strongly correlated with pregnancy-associated insulin resistance, making them potential inflammatory biomarkers for GDM management. The gene discussed is CRP; the disease is gestational diabetes.